Core Viewpoint - The Heilongjiang Provincial Government has issued a set of policy measures to support the high-quality development of the biomanufacturing industry, aiming to enhance technological innovation, promote industrial expansion, and ensure resource allocation to create competitive advantages and seize future development opportunities [2][7]. Group 1: Enhancing Technological Innovation - Support for the construction of innovation platforms in biomanufacturing through collaboration between enterprises and research institutions, with financial rewards for approved national and provincial platforms [3][8]. - Encouragement for tackling core technological challenges in biomanufacturing, with provincial financial support for approved key research projects [3][8]. - Incentives for enterprises to increase R&D investment, with subsidies for qualifying expenditures exceeding 500,000 yuan, matched by provincial and municipal funding [3][8]. - Support for the establishment of pilot testing and verification platforms, with potential subsidies of up to 1 million yuan based on performance evaluations [3][8]. - Promotion of technology transfer activities, providing funding for contracts exceeding 1 million yuan for technology purchases from research institutions [3][8]. Group 2: Promoting Industrial Expansion and Quality Improvement - Financial support for new biomanufacturing projects in key sectors, with subsidies of up to 5 million yuan for fixed asset investments of 20 million yuan or more [4][9]. - Assistance for equipment upgrades in biomanufacturing enterprises to enhance production efficiency and reduce costs [4][9]. - Support for digital transformation using AI, big data, and IoT technologies, with subsidies for recognized digital workshops and smart factories [4][9]. Group 3: Supporting Key Sector Development - Focus on strengthening the biopharmaceutical sector with financial support for clinical trials and production of new drugs and high-end medical devices, with potential rewards of up to 1.5 million yuan [4][9]. - Encouragement for the development of new food products, with one-time rewards for approved new food materials and additives [4][9]. - Promotion of biochemicals with high added value, providing rewards for significant sales achievements in new products [4][9]. Group 4: Resource Allocation and Financial Support - Support for the construction of biomanufacturing parks and infrastructure, with potential bond funding for qualifying projects [5][10]. - Inclusion of biomanufacturing enterprises in key resource allocation for utilities, ensuring priority in energy supply [5][10]. - Financial services support for biomanufacturing enterprises to facilitate listing and access to capital markets, including innovative loan products [5][10]. Group 5: Intellectual Property and Talent Development - Strengthening intellectual property protection for biomanufacturing innovations, with services to expedite patent applications [10][11]. - Encouragement for educational institutions to develop relevant programs and attract high-level talent to the biomanufacturing sector [10][11]. Implementation Timeline - The policy measures are effective from the date of issuance until December 31, 2028, with provisions for adjustments based on national and provincial policy changes [10].

Core Insights - The biomanufacturing sector is gaining momentum with strong policy support and technological advancements, positioning it as a key future industry in China [1][2] - The market size of China's biomanufacturing industry is projected to reach approximately 1.8 trillion yuan by 2030, with significant contributions from food additives and biopharmaceuticals [1][2] Industry Developments - The Ministry of Industry and Information Technology has reported that during the 14th Five-Year Plan, China's biomanufacturing industry is expected to expand steadily, reaching a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The focus of the 14th Five-Year Plan is on the industrialization of technology, emphasizing pilot testing, process scaling, and demonstration line construction [2] Company Initiatives - Ruipu Biotech is investing 680 million yuan in a large-scale microbial protein industrialization demonstration project, aiming for trial production by Q4 2026 [3] - Fuxiang Pharmaceutical is leveraging its expertise in high-end antibiotic fermentation to enhance its microbial protein project, focusing on domestic and international expansion [4] - Yikela Biotech is targeting high-value aquatic feed proteins through a collaboration with Fudan University, aiming to reduce reliance on imported fishmeal [5] Technological Advancements - Synthetic biology is identified as a core technology driving low-carbon production and increased labor productivity across various sectors, including healthcare and industrial manufacturing [2] - The integration of AI with synthetic biology is expected to shift the competitive landscape from single-point breakthroughs to platform-based competition, enhancing R&D efficiency [7] Market Trends - The most promising sub-sectors in biomanufacturing during the 14th Five-Year Plan include high-value biomanufactured products in healthcare, bio-based materials, and service-oriented platforms [6] - The industry is anticipated to experience differentiation and improved quality as companies focus on scalable processes, cost control, and clear downstream applications [2][6]

作为未来产业之一，生物制造赛道近期多点开花、动能充沛。政策层面持续加码，上海市近期印发行动 方案，将生物制造纳入积极引导的新兴产业领域，确立其战略优先级；企业端积极发力，富祥药业通过 成立跨国合资公司推进微生物蛋白全球化布局；科研前沿同步突破，"合成高等生物"先导项目启动，AI 驱动下的生命科学创新持续深化，多方协同发力激活万亿产业新潜力。 ● 本报记者 傅苏颖 万亿赛道根基渐牢 近年来，政策高度聚焦产业化落地与技术突破，形成多层次支撑体系，促进我国生物制造产业蓬勃发 展。 工信部此前披露，"十四五"期间，我国生物制造产业规模稳步扩大，总规模达1.1万亿元，生物发酵产 品产量占全球70%以上。其中食品及添加剂、生物制药等细分领域年产值超4000亿元，推动生物制造成 为新的经济增长点。易凯资本预测，到2030年，中国生物制造市场规模将会接近1.8万亿元。 长城证券化工新材料首席分析师肖亚平在接受中国证券报记者采访时表示，合成生物学技术作为生物制 造的核心支撑，可推动产业实现低碳生产、提升劳动生产率，其成果广泛应用于医疗健康、能源开发、 环境保护、工业制造等多个领域，为解决人类面临的各类发展挑战提供创新解决方案， ...

Core Viewpoint - The article highlights significant progress in the "2030 Pioneer Project" in Jiangxi Province, focusing on the biosynthesis and industrialization of functional nutritional products, including microbial proteins and vitamin B3 derivatives [1][3]. Group 1: Project Achievements - The project has developed efficient cell factories for microbial proteins, vitamin B3 derivatives, β-glucans, 2'-fucosyllactose, and L-valine, with some strains achieving internationally leading fermentation yields [3]. - The "Venetian Fusarium Protein" has been approved as a new food ingredient, marking China's first approval of filamentous fungal microbial protein, thus opening a new avenue for the microbial protein manufacturing industry [3]. - The pilot fermentation yield for vitamin B3 derivatives has reached over 40g/L, surpassing domestic and international reported levels, with a product purity of ≥99.5% [3]. Group 2: Industrialization and Economic Impact - The construction of production lines for tens of thousands of tons of microbial proteins and hundreds of tons of vitamin B3 derivatives is underway, expected to create a new food industry worth billions [3][4]. - The project aims to establish a high-level microbial protein manufacturing system to achieve large-scale, low-cost production, effectively replacing imported soybean protein [4]. Group 3: Collaborative Efforts - The project integrates efforts from enterprises, universities, and government, with Jiangxi Haiwen Biological Technology Co., Ltd. focusing on the entire vitamin B3 industry chain and addressing common industry challenges [5]. - The collaboration involves Jiangxi University and Jiangnan University leading the foundational technology development, while Haiwen Biological drives the industrialization of the technology [5].

Summary of Fuxiang Pharmaceutical Conference Call Company Overview - Fuxiang Pharmaceutical is the largest supplier of sulbactam and the second-largest supplier of tazobactam globally, focusing on the production of antibiotic intermediates and active pharmaceutical ingredients since 2002 [2][5][22]. Industry Insights - The demand for energy storage and power batteries has significantly increased, leading to a rise in prices for VC (Vinyl Carbonate) and FEC (Fluoroethylene Carbonate) products, supported by government policies [2][3]. - The VC additive market has seen a collective shutdown for maintenance by key players, impacting supply by approximately 20,000 tons [8][10]. Key Points Production Capacity and Expansion Plans - Fuxiang plans to expand VC production capacity to 10,000 tons and FEC to 5,000 tons by Q2 2026, with environmental facilities already prepared for rapid expansion [2][4]. - Current VC production capacity is 8,000 tons, with a cost control below 50,000 yuan per ton, while market prices have surged to around 140,000 yuan [3][14]. Financial Performance and Cost Management - The price of LPA (a key raw material) has decreased from 280,000-300,000 yuan per ton to 160,000-170,000 yuan, significantly improving the gross margins for sulbactam and tazobactam [5][22]. - The company has implemented new processes to reduce costs by approximately 15% and has proprietary technology that is significantly cheaper than external sourcing [24][25]. Market Demand and Product Development - Fuxiang maintains an optimistic outlook on the downstream demand for sulbactam and tazobactam, with annual growth projected in the single digits [22]. - The introduction of new drugs has driven growth in the raw material intermediates market [22]. Microbial Protein and Agricultural Projects - Fuxiang is the first company in China to achieve industrialization of filamentous fungal protein at a scale of over 1,000 tons, with plans to expand to 20,000 tons by 2026 [6][27]. - The company is also developing a water-soluble fertilizer project, expected to yield significant benefits upon completion [28][29]. Competitive Landscape - The competitive landscape in the VC additive market is intense, with Fuxiang's main customers including Tianqi Materials and New Zobang, although specific sales proportions were not disclosed [13]. - The company is well-positioned to respond to market fluctuations due to its existing infrastructure and rapid approval processes for expansion [16][17]. Future Outlook - The company anticipates a new price equilibrium in the market, with strategies in place to maintain competitiveness regardless of price fluctuations [18]. - Fuxiang is closely monitoring developments in solid-state battery materials but currently has no active projects in that area [30]. Additional Insights - The microbial protein market is expected to grow due to its nutritional advantages over plant proteins, including zero cholesterol and low sugar content [30]. - The company has made significant investments in patent protection and certifications to support its strategic direction in microbial protein and other innovative products [7].

Group 1: Market Trends and Demand - The price of VC has rapidly increased, driven by the growth in demand for energy storage and power batteries, with current prices around 50,000 CNY/ton [2][3] - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6% [3] - The shipment of lithium batteries for energy storage in China was 265 GWh in the first half of 2025, showing a year-on-year growth of 128% [3] Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC [4] - Plans are in place to increase VC production capacity to 10,000 tons/year by Q2 2026, with potential future expansions to 20,000 tons/year for VC and 5,000 tons/year for FEC depending on market demand [4] Group 3: Pricing and Profitability of Pharmaceutical Products - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is expected to enhance the gross margin of the pharmaceutical manufacturing business [6] - The sales revenue from hezobactam and sulbactam is projected to account for approximately 40% of the company's total revenue in 2024 [6] Group 4: Market Outlook for Pharmaceutical Products - The sales of piperacillin-tazobactam injection exceeded 7 billion CNY in 2023, while the sales of cefoperazone-sulbactam injection surpassed 9 billion CNY, marking a year-on-year growth of 13.39% [6] - New drug approvals are expected to drive demand for upstream raw materials and intermediates, opening new growth avenues for the company [6] Group 5: Microbial Protein Production and Future Plans - The company has an existing production capacity of 1,200 tons/year for microbial protein and is accelerating the construction of a project with a planned capacity of 200,000 tons/year [9] - The microbial protein production process is efficient, sustainable, and free from antibiotics, with applications in various sectors including "meat alternatives" and health products [10] Group 6: Advantages of Amino Acid Water-Soluble Fertilizers - The amino acid water-soluble fertilizers contain essential amino acids and have shown significant effects on plant growth and metabolism [11] - The market outlook is promising due to national policies promoting the reduction of chemical fertilizers and the innovation of green inputs [11]

Core Viewpoint - The company is experiencing significant growth in demand for its products, particularly in the VC and FEC segments, driven by the rapid expansion of the energy storage and power battery markets, alongside strategic capacity expansion plans [1][2]. Group 1: Market Demand and Pricing - Recent rapid increases in VC product prices are attributed to the growing demand from energy storage and power batteries, with VC prices around 50,000 yuan/ton [1]. - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6%, while the shipment of energy storage lithium batteries was 265 GWh, up 128% year-on-year [1]. - The energy storage market in China is expected to exceed 500 GWh in scale, with a year-on-year growth rate of over 50% anticipated [1]. Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC, with plans to increase VC capacity to 10,000 tons/year by Q2 2026 [2]. - Future plans include increasing VC capacity to 20,000 tons/year and FEC capacity to 5,000 tons/year, depending on market demand and industry capacity releases [2]. Group 3: Cost Management and Profitability - The company is focused on reducing production costs for its VC products through technological improvements and has a strong position in cost control within the industry [3]. - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is expected to enhance the gross margin of the company's pharmaceutical manufacturing business [4]. Group 4: Product Development and Market Position - The company is the largest global supplier of sulbactam and a major supplier of tazobactam, with ongoing efforts to expand production capacity for these products [5]. - The company has achieved significant milestones in the microbial protein sector, with a current capacity of 1,200 tons/year and plans for a project that will scale up to 20,000 tons/year [6]. Group 5: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 769 million yuan, a year-on-year decrease of 21.24%, and a net profit attributable to shareholders of -62.75 million yuan [7]. - The company's gross margin stands at 12.05%, with a debt ratio of 51.15% [7].

Summary of Fuxiang Pharmaceutical Conference Call Company Overview - Fuxiang Pharmaceutical is the second-largest producer of tazobactam globally, focusing on high-end antibiotics and cost reduction through new processes, aiming for a 15%-20% cost decrease in collaboration with Jiangxi Normal University [2][3] Key Points Industry Position and Product Lines - Fuxiang Pharmaceutical specializes in compound and high-end antibiotics, with a leading market share in enzyme inhibitors like sulbactam, and is the only supplier with international market certification [3] - The company has a production capacity of 500 tons for sulbactam and 100 tons for tazobactam, with plans to expand tazobactam production to 500 tons by the end of 2025 [4][14] New Energy Sector - Since 2022, Fuxiang has entered the new energy sector, producing lithium battery electrolyte additives VC and FEC, ranking among the top three in VC shipments in 2023 [2][5] - The current production capacity is 8,000 tons for VC and 4,000 tons for FEC, with VC prices rising to 100,000-150,000 yuan per ton due to increased demand from energy storage and power batteries [5][7] - Plans to expand VC production to 10,000 tons and FEC to 5,000 tons by Q2 2026 [5][8] Synthetic Biology Sector - Fuxiang is developing microbial protein products, having received certifications in the US and China, with a current production capacity of 1,200 tons and plans to expand to 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer by Q2 2026 [6][15] - The microbial protein market is projected to reach $290 billion by 2035, with microbial protein accounting for 22% of that demand [15] Cost Management and Profitability - The price of 6-APA has decreased from 300,000 yuan to around 160,000 yuan per ton, positively impacting the gross margin of sulbactam and tazobactam products [12] - Fuxiang's intermediate products, including sulbactam and penem series, contribute approximately 40% to the company's revenue [13] - Current unit costs for VC are below 50,000 yuan, with expectations for further reductions as production capacity increases [9] Market Dynamics and Competition - The recent price surge in VC is attributed to increased demand for energy storage batteries, rising penetration of new energy vehicles, and industry maintenance [7] - Fuxiang aims to maintain its competitive edge through cost control and high purity, despite market fluctuations [21] - The company is confident in its ability to respond to market changes and maintain supply stability without altering long-term plans due to short-term price volatility [19] Future Outlook - Fuxiang plans to achieve a production capacity of 10,000 tons for VC by Q2 2026, with potential further expansion to 20,000 tons depending on market conditions [20] - The company has established subsidiaries to develop C-end products and engage with B-end clients, enhancing its market presence [15][16] Conclusion - Fuxiang Pharmaceutical is strategically positioned in the pharmaceutical and new energy sectors, focusing on cost reduction, capacity expansion, and market responsiveness to sustain its competitive advantage and drive future growth [2][21]

Group 1: Market Trends and Demand - The price of VC has rapidly increased due to the growing demand from energy storage and power batteries, influenced by macro policies and supply-demand changes [2][3] - In the first half of 2025, the cumulative sales of power batteries reached 485.5 GWh, a year-on-year increase of 51.6%, while the shipment of energy storage lithium batteries was 265 GWh, up 128% year-on-year [3] Group 2: Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC and 4,000 tons/year for FEC, with plans to increase VC capacity to 10,000 tons/year by Q2 2026 [3] - Future plans include increasing VC and FEC production capacities to 20,000 tons/year and 5,000 tons/year, respectively, depending on market demand [3] Group 3: Cost Management and Efficiency - The company is leveraging its experience in chemical processes to control production costs effectively, with VC product costs expected to decrease further as capacity increases [4] - The procurement price of 6-APA has decreased by 38% compared to the end of 2024, which is anticipated to enhance the gross margin of the pharmaceutical manufacturing business [6] Group 4: Product Portfolio and Market Position - The company is the largest global supplier of Sulbactam and a major supplier of Tezobactam, with a significant market share and quality assurance [5][6] - The company is expanding its production capacity for Piperacillin, which is in high demand due to increased terminal demand [7] Group 5: New Product Development - The company is the first in China to achieve large-scale industrialization of filamentous fungal protein, with a current capacity of 1,200 tons/year and plans for a 200,000 tons/year project [7] - The new protein has passed technical reviews and is awaiting regulatory approval, which will enable the company to expand its microbial protein business significantly [7]

Core Viewpoint - Microbial protein, also known as single-cell protein (SCP), is derived from microorganisms and is considered a sustainable solution to global protein shortages, with applications in food, feed, and functional ingredients [2]. Group 1: Market Size and Growth Trends - The microbial protein market in China is projected to grow from 2.108 billion yuan in 2024 to 60.005 billion yuan by 2031, with a compound annual growth rate (CAGR) of 65.50% from 2025 to 2031 [4]. - The industry is characterized by short production cycles, high resource utilization efficiency, and environmental friendliness, making it a strategic solution for sustainable food development [4]. Group 2: Product Types and Applications - Fungal microbial protein is expected to generate the highest revenue among the four types of microbial protein, with a market size of 1.024 billion yuan in 2024, accounting for approximately 48.59% of the product types [5]. - Animal feed is the largest application area for microbial protein, projected to reach 1.608 billion yuan in 2024, representing about 76.25% of the market [5]. Group 3: Competitive Landscape - Major players in the Chinese microbial protein market include Alltech, Calysta, Unibio, Metanica, and Sophie's Bionutrients, collectively holding over 76.16% market share in 2024 [5]. - The competition in the industry is expected to intensify in the coming years as more players enter the market [5]. Group 4: Supply Chain Analysis - The upstream supply chain includes fermentation substrates, carbon sources, and nitrogen sources, which are critical for microbial growth and protein synthesis [11]. - The midstream involves microbial cultivation, fermentation processes, and protein extraction, which are key to determining protein yield and quality [11]. - The downstream focuses on protein purification, drying, packaging, and end-use applications, with product safety and functionality being paramount [11]. Group 5: Development Drivers - Global protein demand is rising due to population growth and increased living standards, making microbial protein a vital alternative to traditional animal protein [12]. - Environmental pressures from livestock farming, such as carbon emissions and resource consumption, are driving the shift towards sustainable protein solutions like microbial protein [13]. - Advances in synthetic biology and fermentation technology are reducing production costs and enhancing the competitiveness of microbial protein [13]. Group 6: Development Constraints - High production costs and energy consumption associated with specialized fermentation equipment and purification processes pose challenges for large-scale commercialization [14][15]. - Consumer acceptance remains limited due to psychological barriers regarding the "microbial source" of these proteins, particularly in food and beverage applications [14]. - Regulatory complexities and varying standards across regions can delay market entry for microbial protein products [16].